Concerted action of IFN-? and IFN-? induces local NK cell immunity and halts cancer growth.

ABSTRACT: Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer. No significant improvement has been reported with currently available systemic therapies. IFN-? has been tested in both clinic and animal models and only moderate benefits have been observed. In animal models, similar modest antitumor efficacy has also been reported for IFN-?, a new type of IFN that acts through its own receptor complex. In the present study, the antitumor efficacy of the combination of IFN-? and IFN-? was tested in the BNL mouse hepatoma model. This study was accomplished by using either engineered tumor cells (IFN-?/IFN-? gene therapy) or by directly injecting tumor-bearing mice with IFN-?/IFN-?. Both approaches demonstrated that IFN-?/IFN-? combination therapy was more efficacious than IFN monotherapy based on either IFN-? or IFN-?. In complement to tumor surgery, IFN-?/IFN-? combination induced complete tumor remission. Highest antitumor efficacy has been obtained following local administration of IFN-?/IFN-? combination at the tumor site that was associated with strong NK cells tumor infiltration. This supports the use of IFN-?/IFN-? combination as a new cancer immunotherapy for stimulating antitumor response after cancer surgery.

SUBMITTER: Lasfar A 

PROVIDER: S-EPMC5226505 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature